Showing 6001-6010 of 9536 results for "".
- Merz to Acquire Ulthera, Inc.https://practicaldermatology.com/news/20140630-merz_to_acquire_ulthera_inc/2459184/Merz and Ulthera have entered a definitive merger agreement pursuant to which Merz will acquire Ulthera, Inc, a global medical device company focused on developing and commercializing technologies for aesthetic and medical applications using its therapeutic ultrasound platform technology. Valued
- New National Psoriasis Foundation Program Prioritizes Psoriatic Arthritishttps://practicaldermatology.com/news/20140626-new_national_psoriasis_foundation_program_prioritizes_psoriatic_arthritis/2459186/According to the National Psoriasis Foundation (NPF), millions of Americans with psoriatic arthritis struggle to get the health care and treatments they need to manage their condition. To help change that, the NPF launched the largest realignment and expansion of its psoriatic a
- Acne Cure Alliance Announces Call for Dermatologist to Lead Integrative Acne Treatment and Research Centerhttps://practicaldermatology.com/news/20140626-acne_cure_alliance_announces_call_for_dermatologist_to_lead_integrative_acne_treatment_and_research_center/2459187/The Acne Cure Alliance, a non-profit foundation, is actively recruiting a visionary acne expert to lead the Acne Treatment and Research Center - a new and unique integrative practice approach for acne patients. This is an opportunity for a Board-certified dermatologist to join the Board of D
- AMBI® Skincare Names Model Search Winnerhttps://practicaldermatology.com/news/20140623-ambi_skincare_names_model_search_winner/2459194/Charnee Long, 21, is the Grand Prize Winner of the first-ever nationwide AMBI® Model Search. Charnee was one of 10 finalists selected from a pool of more than 6,099 entrants. She will be featured in a national print campaign, receiving a three day/two night trip to New York City for a pro
- Verisante Technology, Inc. Announces 2014 First Quarter Results and Provides Operational Updatehttps://practicaldermatology.com/news/20140623-verisante_technology_inc_announces_2014_first_quarter_results_and_provides_operational_update/2459195/Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF) (the “Company” or “Verisante”), a leader in cancer detection technology, announced today that the Company has released its financial results for the first quarter ended March 31, 2014 .
- Verisante Technology, Inc. Partners with the BC Cancer Foundation to Showcase Aura™ for Skin Cancer Detectionhttps://practicaldermatology.com/news/20140623-verisante_technology_inc_partners_with_the_bc_cancer_foundation_to_showcase_aura_for_skin_cancer_detection/2459196/Verisante Technology, Inc. is partnering with the BC Cancer Foundation to showcase Verisante Aura™, a device for the detection of skin cancer. Verisante has placed an Aura™ at the Foundation's Provincial Office in Vancouver for display and educa
- Valeant Commences Exchange Offer For Allerganhttps://practicaldermatology.com/news/20140618-valeant_commences_exchange_offer_for_allergan/2459201/
- Celsus Therapeutics Receives Ministry of Health of Israel Approval to Conduct Phase II Trial of MRX-6 in Pediatric Atopic Dermatitis Patientshttps://practicaldermatology.com/news/20140617-a_new_class_of_treatment_can_to_be_used_for_atopic_dermatitis/2459202/Celsus Therapeutics Plc received approval from Ministry of Health of Israel for Phase II Trial of MRX-6 in Pediatric Atopic Dermatitis Patients. The Company plans to conduct the study in five to six centers in Israel as well as Argentina. They plan to enroll 80 pediatric patient
- Spain's LETI Laboratories Launches Leading Atopic Skincare Line to U.S. Markethttps://practicaldermatology.com/news/20140617-spains_leti_laboratories_launches_leading_atopic_skincare_line_to_us_market/2459203/DermWORX Professional Skincare and LETI Laboratories, headquartered in Barcelona, Spain, will launch a series of top European dermatological products in the United States. The series includes: LETI's leading dermatology line for atopic skin, AT4, which DermWORX will market to U.S. heal
- Valeant Pharmaceuticals Announces Planned Management Departurehttps://practicaldermatology.com/news/20140616-valeant_pharmaceuticals_announces_planned_management_departure/2459206/Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) today announced that Ryan Weldon, Valeant's Executive Vice President and Company Group Chairman, will be leaving the Company following the divestiture of all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport ow